See more : Taiheiyo Kouhatsu Incorporated (8835.T) Income Statement Analysis – Financial Results
Complete financial analysis of XBiotech Inc. (XBIT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of XBiotech Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- myFC Holding AB (publ) (MYFC.ST) Income Statement Analysis – Financial Results
- TRF Limited (TRF.NS) Income Statement Analysis – Financial Results
- Iovance Biotherapeutics, Inc. (0JDK.L) Income Statement Analysis – Financial Results
- Pono Capital Corp. (PONO) Income Statement Analysis – Financial Results
- Gladstone Capital Corporation – (GLADL) Income Statement Analysis – Financial Results
XBiotech Inc. (XBIT)
About XBiotech Inc.
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 4.01M | 18.39M | 44.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.74M | 651.00K | 5.82M | 34.55M | 2.36M | 2.43M | 1.48M | 698.00K | 699.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.74M | 3.36M | 12.57M | 9.45M | -2.36M | -2.43M | -1.48M | -698.00K | -699.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 83.77% | 68.36% | 21.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 32.85M | 31.54M | 28.27M | 9.53M | 24.09M | 15.73M | 26.42M | 42.49M | 31.31M | 14.33M | 7.94M | 13.33M |
| General & Administrative | 4.66M | 6.31M | 9.39M | 18.20M | 7.14M | 5.27M | 7.64M | 10.28M | 6.20M | 7.45M | 1.99M | 1.83M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.66M | 6.31M | 9.39M | 18.20M | 7.14M | 5.27M | 7.64M | 10.28M | 6.20M | 7.45M | 1.99M | 1.83M |
| Other Expenses | 0.00 | -121.00K | -132.00K | -503.00K | 750.01M | 4.00K | 0.00 | 0.00 | 21.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 37.51M | 37.85M | 37.66M | 27.73M | 31.23M | 20.99M | 34.06M | 52.76M | 37.51M | 21.78M | 9.93M | 15.16M |
| Cost & Expenses | 37.51M | 38.50M | 43.48M | 62.27M | 31.23M | 20.99M | 34.06M | 52.76M | 37.51M | 21.78M | 9.93M | 15.16M |
| Interest Income | 10.42M | 3.82M | 467.00K | 2.46M | 564.00K | 400.00K | 354.00K | 49.00K | 0.00 | 1.00K | 0.00 | 3.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.74M | 2.61M | 2.65M | 2.24M | 2.36M | 2.43M | 1.48M | 698.00K | 699.00K | 664.00K | 784.00K | 946.00K |
| EBITDA | -35.77M | -31.88M | -22.43M | -16.04M | -28.87M | -18.71M | -32.58M | -52.06M | -36.81M | -21.11M | -9.14M | -14.21M |
| EBITDA Ratio | 0.00% | -725.09% | -118.10% | -44.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -37.51M | -34.49M | -25.08M | -18.28M | -31.23M | -20.99M | -34.06M | -52.76M | -37.51M | -21.78M | -9.93M | -15.16M |
| Operating Income Ratio | 0.00% | -860.10% | -136.36% | -41.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 13.20M | 902.00K | -376.00K | 5.45M | 749.69M | -144.00K | 909.00K | 2.00K | 27.00K | 54.00K | -2.00K | 3.00K |
| Income Before Tax | -24.31M | -33.59M | -25.46M | -12.83M | 718.45M | -21.14M | -33.15M | -52.76M | -37.48M | -21.72M | -9.93M | -15.16M |
| Income Before Tax Ratio | 0.00% | -837.61% | -138.40% | -29.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 244.00K | -688.00K | -8.04M | -1.61M | 49.82M | -144.00K | -909.00K | -2.00K | -6.00K | -54.00K | 2.00K | 0.00 |
| Net Income | -24.56M | -32.90M | -17.41M | -11.22M | 668.63M | -21.14M | -33.15M | -52.76M | -37.48M | -21.72M | -9.93M | -15.16M |
| Net Income Ratio | 0.00% | -820.45% | -94.67% | -25.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.81 | -1.08 | -0.58 | -0.36 | 17.17 | -0.59 | -0.95 | -1.63 | -1.22 | -0.68 | -0.31 | -0.48 |
| EPS Diluted | -0.81 | -1.08 | -0.58 | -0.36 | 14.44 | -0.59 | -0.95 | -1.63 | -1.22 | -0.68 | -0.31 | -0.48 |
| Weighted Avg Shares Out | 30.32M | 30.44M | 30.04M | 30.82M | 38.95M | 35.80M | 34.88M | 32.40M | 30.80M | 31.72M | 31.72M | 31.72M |
| Weighted Avg Shares Out (Dil) | 30.44M | 30.44M | 30.04M | 30.82M | 46.32M | 35.80M | 34.88M | 32.40M | 30.80M | 31.72M | 31.72M | 31.72M |
XBiotech Announces Payment of Dividend to Holders of Common Stock
Company distributed USD $75 Million to Shareholders Company distributed USD $75 Million to Shareholders
XBiotech Stock Increased 7.41%: Why It Happened
The stock price of XBiotech Inc (NASDAQ: XBIT) increased by 7.41%. This is why it happened.
XBiotech Announces Dividend to Holders of Common Stock
AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.'s (NASDAQ: XBIT) (“XBiotech”) Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to an aggregate of $75 million, to holders of its common...
XBiotech Announces Receipt of $75 Million from Sale of Antibody
Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody
XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer
XB2001 Is a Novel Therapy that Interrupts Inflammation to Potentially Block Growth and Spread of Tumors and to Reduce Toxicity of Chemotherapy Treatment XB2001 Is a Novel Therapy that Interrupts Inflammation to Potentially Block Growth and Spread of Tumors and...
XBiotech To Test New Drug Candidate Combined With Approved Treatment In Pancreatic Cancer
The FDA has signed off Phase 1/2 clinical study to evaluate XBiotech Inc's (NASDAQ: XBIT) XB2001 when added to the ONIVYDE/5-FU combination therapy for treating patients with pancreatic cancer. The Phase 1 portion of the study will examine increasing doses of XBiotech's new drug and...
FDA Gives Go-Ahead for XBiotech's Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer
XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer
Top Small-Cap Stocks for March 2021
These are the small-cap stocks with the best value, fastest growth, and most momentum for March 2021.
XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain
With New Infectious Strain Rapidly Spreading, XBiotech Establishes Data Indicating its Candidate True Human™ COVID-19 Therapy may be Effective for Treating New Mutant Strain With New Infectious Strain Rapidly Spreading, XBiotech Establishes Data Indicating its Candidate True Human™ COVID-19 Therapy...
XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy
Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D. Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D.
Source: https://incomestatements.info
Category: Stock Reports